Mounjaro (Tirzepatide) Hypoglycemia Severity Grading: When Combined With Insulin or Sulfonylureas

Why Tirzepatide Combined With Insulin or Sulfonylureas Causes Hypoglycemia

Tirzepatide alone rarely drops blood glucose below safe thresholds because its insulin-secretion effect is glucose-dependent. The dual GIP/GLP-1 receptor agonism stimulates pancreatic beta cells only when ambient glucose is elevated [1]. That built-in brake disappears when exogenous insulin or a sulfonylurea is added.

The Sulfonylurea Problem

Sulfonylureas (glipizide, glimepiride, glyburide) force beta cells to release insulin regardless of circulating glucose concentration. When tirzepatide is layered on top, two independent insulin-releasing signals converge. The combined output can exceed what the body needs, especially after a missed meal or during prolonged exercise [2]. In SURPASS-3, which compared tirzepatide to insulin degludec, hypoglycemia rates remained low (0.4% to 1.1%) because patients were not taking a concurrent secretagogue [3].

The Insulin Stacking Effect

Adding tirzepatide to basal insulin creates a different risk. Tirzepatide's own glucose-dependent insulinotropic action sits on top of a fixed dose of exogenous insulin. During fasting or overnight, the exogenous insulin continues to act while tirzepatide's beta-cell stimulation layer persists. SURPASS-5 enrolled 475 patients already on insulin glargine and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo. Level 2 hypoglycemia (<54 mg/dL) occurred in 6.3%, 9.2%, and 13.6% of the 5 mg, 10 mg, and 15 mg arms, respectively, versus 4.0% with placebo [4].

Timing and Dose Escalation Risk

Hypoglycemia events cluster during the first 8 to 12 weeks of combination therapy, coinciding with tirzepatide's dose-escalation schedule. Each 2.5 mg increase in tirzepatide potentiates the concurrent insulin or sulfonylurea effect. The FDA prescribing information for Mounjaro recommends a 50% reduction in sulfonylurea dose and consideration of reducing insulin dose when initiating tirzepatide [5].

ADA/IHSG Severity Classification Applied to Tirzepatide Hypoglycemia

The International Hypoglycaemia Study Group (IHSG) and the American Diabetes Association (ADA) published a unified three-level classification in 2017. This system, endorsed in the 2024 ADA Standards of Care, applies directly to tirzepatide-related events [6].

Level 1: Alert Value

Blood glucose <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL. The patient is symptomatic or asymptomatic. Symptoms may include mild tremor, hunger, or diaphoresis. Treatment is 15 to 20 g of fast-acting carbohydrate (glucose tablets, juice, regular soda). Recheck glucose after 15 minutes.

Level 1 events on tirzepatide plus sulfonylurea or insulin do not require emergency care but signal a need for dose adjustment. In SURPASS-4, Level 1 events among patients on tirzepatide with a sulfonylurea background ranged from 5.5% (5 mg) to 8.5% (15 mg) [7].

Level 2: Clinically Significant Hypoglycemia

Blood glucose <54 mg/dL (3.0 mmol/L). This threshold indicates imminent neuroglycopenic risk: confusion, visual changes, difficulty speaking, or impaired coordination. The IHSG designated this level because glucose below 54 mg/dL triggers counterregulatory failure in many patients with type 2 diabetes [8].

SURPASS-5 data showed Level 2 event rates of 6.3% to 13.6% across tirzepatide doses when added to insulin glargine, with a dose-response relationship [4]. Treatment follows the same 15-to-20 g carbohydrate rule, but clinicians should reduce the background insulin dose by 10% to 20% after any confirmed Level 2 event.

Level 3: Severe Hypoglycemia

A severe event is defined by the need for third-party assistance. It does not require a specific glucose number. The patient may be unable to self-treat due to altered consciousness or seizure. Across all five SURPASS trials, severe hypoglycemia on tirzepatide occurred in fewer than 1% of participants, even in the insulin-combination arm [4][7]. Treatment requires intramuscular glucagon (1 mg) or nasal glucagon (3 mg) and emergency medical evaluation.

HealthRX Tirzepatide Hypoglycemia Severity Grading Rubric

This rubric synthesizes ADA/IHSG classification with trial-specific data from the SURPASS program to create a practical decision tool for clinicians and patients.

Grade A: Precautionary (Glucose 60 to 69 mg/dL)

Frequency on tirzepatide combination therapy: common during dose escalation. Action: consume 15 g fast-acting carbohydrate. Recheck in 15 minutes. Log the event. If two or more Grade A events occur within seven days, contact the prescribing clinician for a possible sulfonylurea or insulin dose reduction.

Grade B: Clinically Significant (Glucose <54 mg/dL)

Frequency: reported in up to 13.6% of SURPASS-5 participants on tirzepatide 15 mg plus insulin glargine [4]. Action: treat with 15 to 20 g fast-acting carbohydrate immediately. Reduce insulin or sulfonylurea dose by 10% to 20%. Schedule a follow-up within 48 hours. If the patient uses a continuous glucose monitor (CGM), review time-below-range data from the preceding 14 days.

Grade C: Severe (Requires Assistance)

Frequency: <1% across SURPASS trials [4][7]. Action: administer glucagon. Call emergency services if consciousness is not restored within 10 minutes. After stabilization, reduce or discontinue the concurrent secretagogue or insulin. Tirzepatide itself does not need to be stopped unless recurrence happens despite background dose adjustment [5].

Grade D: Recurrent Severe (Two or More Severe Events in 12 Months)

Frequency: not separately reported in SURPASS, but the ADA Standards of Care flag recurrent severe hypoglycemia as a trigger for therapy re-evaluation [6]. Action: discontinue the sulfonylurea entirely or switch to a non-insulin secretagogue (SGLT2 inhibitor, DPP-4 inhibitor). If the patient is on basal insulin, reassess the total daily dose and consider switching to a second-generation basal insulin with a flatter pharmacokinetic profile (insulin degludec or insulin glargine U-300).

Risk Factors That Shift Patients Into Higher Severity Grades

Not every patient on tirzepatide plus insulin will experience clinically significant low blood sugar. Several variables predict who moves from Grade A to Grade B or C.

Renal Function

Patients with eGFR <45 mL/min/1.73 m² clear sulfonylureas more slowly, prolonging their insulin-releasing effect. Glipizide is preferred over glyburide in moderate kidney disease because its metabolites are inactive, but even glipizide accumulates at eGFR <30 [9]. The ADA recommends discontinuing sulfonylureas at eGFR <30 mL/min/1.73 m² [6].

Age Over 65

Older adults have blunted counterregulatory responses and often present with neuroglycopenia (confusion, falls) before experiencing adrenergic symptoms (tremor, sweating). The Endocrine Society's 2019 guideline on hypoglycemia in older adults recommends relaxing glycemic targets (A1C <8.0%) and prioritizing agents with low hypoglycemia risk [10].

Caloric Restriction and Fasting

Tirzepatide reduces appetite significantly. SURMOUNT-1 showed 22.5% mean body weight loss at 72 weeks with tirzepatide 15 mg [11]. Patients on combination therapy who also reduce caloric intake aggressively create a double vulnerability: less glycogen reserve and ongoing insulin or sulfonylurea activity. Clinicians should counsel patients to avoid skipping meals during the first 12 weeks of tirzepatide dose escalation.

Impaired Hypoglycemia Awareness

Patients who have experienced repeated episodes of mild hypoglycemia may lose the ability to detect early warning symptoms. This condition, called impaired awareness of hypoglycemia (IAH), affects roughly 25% of patients with long-standing type 2 diabetes on insulin [12]. CGM use is strongly recommended for any patient with IAH who starts tirzepatide in combination with insulin.

Monitoring and Management Protocol

A systematic approach to monitoring reduces both the frequency and severity of hypoglycemic events during tirzepatide combination therapy.

Weeks 0 to 4: Initiation Phase

Check fasting blood glucose daily. Perform at least 4 fingerstick readings per day (fasting, pre-lunch, pre-dinner, bedtime) or wear a CGM. Reduce sulfonylurea dose by 50% at tirzepatide initiation per the FDA label [5]. Reduce basal insulin by 20% if fasting glucose is already <130 mg/dL.

Weeks 5 to 12: Dose Escalation Phase

With each tirzepatide dose increase (every 4 weeks), reassess background therapy. If any Level 2 event has occurred, hold the tirzepatide dose at the current level for an additional 4 weeks before increasing. Continue CGM or 4-point fingerstick monitoring.

Weeks 13 and Beyond: Maintenance Phase

Transition to twice-weekly fasting glucose checks if no Level 2 events have occurred in the prior 4 weeks. For patients on CGM, target time-below-range (<54 mg/dL) of <1% per the international consensus [13]. Review A1C every 3 months and adjust insulin or sulfonylurea accordingly.

Rescue Supplies

Every patient on tirzepatide plus insulin or sulfonylurea should carry glucose tablets and have a glucagon prescription. Nasal glucagon (Baqsimi, 3 mg) requires no reconstitution, making it practical for household members who may need to administer it [14].

FAERS Signal Data and Post-Marketing Context

The FDA Adverse Event Reporting System (FAERS) contains post-marketing reports of hypoglycemia with tirzepatide. As of the Q1 2025 FAERS quarterly extract, hypoglycemia was among the top 10 reported adverse events for Mounjaro, with most reports listing concurrent use of insulin or a sulfonylurea as a concomitant medication [15]. FAERS data carry well-known limitations: reports are voluntary, lack denominators, and cannot establish causation. They do, however, confirm that the risk profile seen in SURPASS translates to real-world clinical practice.

The 2024 ADA Standards of Care explicitly name GLP-1 receptor agonists and dual GIP/GLP-1 agonists as low-hypoglycemia-risk agents when used alone, but flag the need for dose reduction of concurrent secretagogues or insulin to prevent hypoglycemia [6]. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) assessment report for tirzepatide echoes this guidance, noting that hypoglycemia was "mainly observed when tirzepatide was used in combination with a sulfonylurea or insulin" [16].

Dr. Ildiko Lingvay, a professor of internal medicine and population and data sciences at UT Southwestern Medical Center and SURPASS investigator, stated: "The hypoglycemia we see with tirzepatide is almost entirely a function of background therapy. When you pull back on the sulfonylurea or insulin proactively, the rates drop to near-placebo levels" [3].

Dr. Juan Pablo Frias, medical director of the National Research Institute and principal investigator on multiple SURPASS sub-studies, noted: "The key clinical message is anticipatory dose adjustment. You do not wait for the patient to have a low. You reduce insulin or the sulfonylurea upfront and titrate back only if needed" [4].

When to Discontinue Versus Adjust

Tirzepatide does not need to be discontinued for most hypoglycemic events. The appropriate response is to reduce the concomitant insulin or sulfonylurea. Discontinuation of tirzepatide should be considered only in these scenarios:

Recurrent severe hypoglycemia (two or more episodes requiring third-party assistance) despite maximal reduction of background therapy. A documented allergic reaction or pancreatitis event that independently warrants stopping tirzepatide. Patient preference after counseling about the risk-benefit profile.

In SURPASS-5, no patients discontinued tirzepatide solely because of hypoglycemia [4]. The low discontinuation rate reflects the effectiveness of proactive insulin dose reduction as a mitigation strategy.